LeonaBio

LeonaBio EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of LeonaBio (LONA) as of Nov 11, 2026 is -0.05. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -0.42 — a change of -88.02% (higher).

EV/EBITDA

-0.05

YoY

-88.02%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of LeonaBio is 2025 -0.05 . EV/EBITDA (Enterprise Value to EBITDA) of LeonaBio was 2024 -0.42 . It decreases by -88.02% higher compared to the previous year.

The LeonaBio EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-17.69 USD
Jan 1, 2019
-16.92 USD
Jan 1, 2020
4.55 USD
Jan 1, 2021
2.49 USD
Jan 1, 2022
1.02 USD
Jan 1, 2023
0.42 USD
Jan 1, 2024
-0.42 USD
Jan 1, 2025
-0.05 USD
The LeonaBio EV/EBITDA history
YEAREV/EBITDAYoY
-0.05-88.02%
-0.42-199.81%
0.42-58.34%
1.02-59.11%
2.49-45.37%
4.55-126.89%
-16.92-4.35%
-17.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

EV/EBITDA (Enterprise Value to EBITDA) of LeonaBio is -0.05 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of LeonaBio changed from -0.42 to -0.05, representing a -88.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) LeonaBio since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s LeonaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — LeonaBio

All Key Metrics — LeonaBio